Genetic markers associated with progression in early mycosis fungoides
Authors:
- 31 October 2013
- journal article
- research article
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 28 (11) , 1431-1435
Abstract
Background: Mycosis fungoides (MF) is a rare, but potentially devastating malignancy. It classically presents with cutaneous patches and plaques and can progress to tumours on the skin with lymph node, blood and visceral involvement. While most patients with MF have a relatively benign disease course, a subset of patients will develop progressive disease that is often fatal.Objective: The aim of this study was to identify genetic markers in early MF limited to the skin (stages IA‐IIA) that distinguish those patients who will have progressive disease from those who will not, so that early appropriate treatment may be instituted.Methods: The study includes 18 patients who were diagnosed with early stage MF at the time of biopsy and had follow‐up to determine which patients developed progressive disease. RNA was extracted from skin biopsy specimens and analysed for expression of CD3, FOXP3, IFNγ, Interleukin (IL)‐4, IL‐13, KIR3DL2, MICB, PLS3 and STAT4 by quantitative real‐time polymerase chain reaction.Results/Conclusions: Reduced expression of FOXP3 and STAT4 and increased expression of IL‐4 relative to CD3 expression levels were significantly associated with MF progression. Further studies will be needed to fully assess the usefulness of these genetic markers to predict disease progression and guide treatment options in patients diagnosed with early MF.Keywords
Funding Information
- Dermatology Foundation
- NIH/NCI (K12CA090625)
- Vanderbilt Department of Medicine/Dermatology (R01CA148950)
- Vanderbilt Department of Pathology, Microbiology and Immunology
- CTSA (UL1TR000445)
- National Center for Advancing Translational Sciences
- American Cancer Society (IRG-58-009-51)
This publication has 28 references indexed in Scilit:
- Regulatory T cells and immunodeficiency in mycosis fungoides and Sézary syndromeLeukemia, 2011
- Transcriptional Profiles Predict Disease Outcome in Patients with Cutaneous T-Cell LymphomaClinical Cancer Research, 2010
- Paucity of intraepidermal FoxP3‐positive T cells in cutaneous T‐cell lymphoma in contrast with spongiotic and lichenoid dermatitisJournal of Cutaneous Pathology, 2010
- Poor prognosis in non-Caucasian patients with early-onset mycosis fungoidesJournal of the American Academy of Dermatology, 2009
- Expression of T-plastin, FoxP3 and other tumor-associated markers by leukemic T-cells of cutaneous T-cell lymphomaLeukemia & Lymphoma, 2008
- Regulatory T‐cell phenotype in association with large cell transformation of mycosis fungoidesEuropean Journal of Haematology, 2006
- Quantitative PCR on 5 genes reliably identifies CTCL patients with 5% to 99% circulating tumor cells with 90% accuracyBlood, 2006
- Mycosis fungoides shows concurrent deregulation of multiple genes involved in the TNF signaling pathway: an expression profile studyBlood, 2003
- Prognostic factor analysis in mycosis fungoides/Sézary syndromeJournal of the American Academy of Dermatology, 1999
- TH1 and TH2 Cells: Different Patterns of Lymphokine Secretion Lead to Different Functional PropertiesAnnual Review of Immunology, 1989